 Tamoxifen
"Tamoxifen" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
One of the SELECTIVE ESTROGEN RECEPTOR MODULATORS with tissue-specific activities. Tamoxifen acts as an anti-estrogen (inhibiting agent) in the mammary tissue, but as an estrogen (stimulating agent) in cholesterol metabolism, bone density, and cell proliferation in the ENDOMETRIUM.
| Descriptor ID |
D013629
|
| MeSH Number(s) |
D02.455.426.559.389.150.700.900
|
| Concept/Terms |
ICI-46474- ICI-46474
- ICI 46474
- ICI46474
- ICI-46,474
- ICI 46,474
- ICI46,474
|
Below are MeSH descriptors whose meaning is more general than "Tamoxifen".
Below are MeSH descriptors whose meaning is more specific than "Tamoxifen".
This graph shows the total number of publications written about "Tamoxifen" by people in this website by year, and whether "Tamoxifen" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1991 | 1 | 0 | 1 | | 1992 | 1 | 1 | 2 | | 1993 | 2 | 0 | 2 | | 1994 | 3 | 1 | 4 | | 1995 | 1 | 0 | 1 | | 1997 | 1 | 0 | 1 | | 1998 | 0 | 1 | 1 | | 1999 | 2 | 2 | 4 | | 2000 | 3 | 2 | 5 | | 2001 | 0 | 1 | 1 | | 2002 | 1 | 1 | 2 | | 2003 | 2 | 1 | 3 | | 2004 | 2 | 2 | 4 | | 2005 | 0 | 1 | 1 | | 2006 | 2 | 1 | 3 | | 2007 | 3 | 3 | 6 | | 2008 | 5 | 1 | 6 | | 2009 | 2 | 3 | 5 | | 2010 | 3 | 4 | 7 | | 2011 | 0 | 1 | 1 | | 2012 | 1 | 3 | 4 | | 2013 | 1 | 1 | 2 | | 2014 | 3 | 6 | 9 | | 2015 | 0 | 1 | 1 | | 2016 | 3 | 4 | 7 | | 2017 | 1 | 1 | 2 | | 2018 | 0 | 3 | 3 | | 2019 | 1 | 5 | 6 | | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Tamoxifen" by people in Profiles.
-
Golla JP, Kandyliari A, Tan WY, Chen Y, Orlicky DJ, Thompson DC, Shah YM, Vasiliou V. Interplay between APC and ALDH1B1 in a newly developed mouse model of colorectal cancer. Chem Biol Interact. 2020 Nov 01; 331:109274.
-
Gewin LS, Summers ME, Harral JW, Gaskill CF, Khodo SN, Neelisetty S, Sullivan TM, Hopp K, Reese JJ, Klemm DJ, Kon V, Ess KC, Shi W, Majka SM. Inactivation of Tsc2 in Abcg2 lineage-derived cells drives the appearance of polycystic lesions and fibrosis in the adult kidney. Am J Physiol Renal Physiol. 2019 11 01; 317(5):F1201-F1210.
-
Chen Y, Ernst P. Hematopoietic transformation in the absence of MLL1/KMT2A: distinctions in target gene reactivation. Cell Cycle. 2019 07; 18(14):1525-1531.
-
Wassermann J, Gelber SI, Rosenberg SM, Ruddy KJ, Tamimi RM, Schapira L, Borges VF, Come SE, Meyer ME, Partridge AH. Nonadherent behaviors among young women on adjuvant endocrine therapy for breast cancer. Cancer. 2019 09 15; 125(18):3266-3274.
-
von Hippel C, Rosenberg SM, Austin SB, Sprunck-Harrild K, Ruddy KJ, Schapira L, Come S, Borges VF, Partridge AH. Identifying distinct trajectories of change in young breast cancer survivors' sexual functioning. Psychooncology. 2019 05; 28(5):1033-1040.
-
Bossart EA, Tasdemir N, Sikora MJ, Bahreini A, Levine KM, Chen J, Basudan A, Jacobsen BM, Burns TF, Oesterreich S. SNAIL is induced by tamoxifen and leads to growth inhibition in invasive lobular breast carcinoma. Breast Cancer Res Treat. 2019 Jun; 175(2):327-337.
-
Selmin OI, Donovan MG, Skovan B, Paine-Murieta GD, Romagnolo DF. Arsenic-induced BRCA1 CpG promoter methylation is associated with the downregulation of ERa and resistance to tamoxifen in MCF7 breast cancer cells and mouse mammary tumor xenografts. Int J Oncol. 2019 Mar; 54(3):869-878.
-
Hobeika E, Dautzenberg M, Levit-Zerdoun E, Pelanda R, Reth M. Conditional Selection of B Cells in Mice With an Inducible B Cell Development. Front Immunol. 2018; 9:1806.
-
Wellberg EA, Kabos P, Gillen AE, Jacobsen BM, Brechbuhl HM, Johnson SJ, Rudolph MC, Edgerton SM, Thor AD, Anderson SM, Elias A, Zhou XK, Iyengar NM, Morrow M, Falcone DJ, El-Hely O, Dannenberg AJ, Sartorius CA, MacLean PS. FGFR1 underlies obesity-associated progression of estrogen receptor-positive breast cancer after estrogen deprivation. JCI Insight. 2018 07 26; 3(14).
-
Abraham J, Caldera H, Coleman R, Elias A, Goetz MP, Kittaneh M, Lower E, Mahtani R, Terry Mamounas E, Pegram M, Rugo H, Schwartzberg L, Traina T, Vogel C. Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG). Breast Cancer Res Treat. 2018 May; 169(1):1-7.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|